Edwards Lifesciences Corp
NYSE:EW

Watchlist Manager
Edwards Lifesciences Corp Logo
Edwards Lifesciences Corp
NYSE:EW
Watchlist
Price: 84.32 USD -2.17% Market Closed
Market Cap: 48.9B USD

Edwards Lifesciences Corp
Cash & Cash Equivalents

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Edwards Lifesciences Corp
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Edwards Lifesciences Corp
NYSE:EW
Cash & Cash Equivalents
$2.7B
CAGR 3-Years
29%
CAGR 5-Years
21%
CAGR 10-Years
15%
Boston Scientific Corp
NYSE:BSX
Cash & Cash Equivalents
$1.3B
CAGR 3-Years
56%
CAGR 5-Years
-9%
CAGR 10-Years
14%
Stryker Corp
NYSE:SYK
Cash & Cash Equivalents
$3.3B
CAGR 3-Years
32%
CAGR 5-Years
-14%
CAGR 10-Years
0%
Abbott Laboratories
NYSE:ABT
Cash & Cash Equivalents
$7.5B
CAGR 3-Years
-8%
CAGR 5-Years
11%
CAGR 10-Years
9%
IDEXX Laboratories Inc
NASDAQ:IDXX
Cash & Cash Equivalents
$208.2m
CAGR 3-Years
28%
CAGR 5-Years
3%
CAGR 10-Years
4%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash & Cash Equivalents
$8.4B
CAGR 3-Years
76%
CAGR 5-Years
44%
CAGR 10-Years
26%
No Stocks Found

Edwards Lifesciences Corp
Glance View

Nestled at the intersection of medical innovation and patient care, Edwards Lifesciences Corp. has long been a pioneer in the field of heart disease solutions. Emerging from its origins in the 1950s, the company has consistently focused on advancing heart valve technology, a critical area given the prevalence and severity of cardiovascular diseases. Their journey began with the development of the first artificial heart valve, setting a foundation of innovation that continues to propel the company forward. Today, Edwards is renowned for its leadership in transcatheter aortic valve replacement (TAVR) technology, an area that revolutionizes the treatment of aortic stenosis, a condition that narrows heart valves and impedes blood flow. This shift from open-heart surgeries to less invasive procedures, facilitated by Edwards' products, has marked a significant turning point in patient care, minimizing recovery times and enhancing patient outcomes. Financially, Edwards Lifesciences thrives on a robust business model centered around its technologically advanced heart valve systems and critical care technologies. The company operates through a direct sales force as well as strategic partnerships, ensuring their devices reach hospitals and healthcare providers globally. Their commitment to research and development ensures a steady pipeline of innovative products, which not only differentiates them in the market but also drives their profitability. Revenue streams are primarily fueled by the sales of their TAVR systems, surgical heart valves, and monitoring technologies—each designed to meet the complex and evolving needs of patients with structural heart diseases. By continually investing in cutting-edge technology and expanding their global reach, Edwards Lifesciences not only supports its bottom line but also positions itself as a leader in the transformative field of medical device innovation.

EW Intrinsic Value
59.79 USD
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Edwards Lifesciences Corp's Cash & Cash Equivalents?
Cash & Cash Equivalents
2.7B USD

Based on the financial report for Sep 30, 2025, Edwards Lifesciences Corp's Cash & Cash Equivalents amounts to 2.7B USD.

What is Edwards Lifesciences Corp's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
15%

Over the last year, the Cash & Cash Equivalents growth was -27%. The average annual Cash & Cash Equivalents growth rates for Edwards Lifesciences Corp have been 29% over the past three years , 21% over the past five years , and 15% over the past ten years .

Back to Top